STOCK MARKET BSE NSE

Research reveals long term benefits of Covaxin  

The study, funded by the Centre's department of biotechnology has shown that T and B cell memory responses generated by Covaxin measures.

Published: 21st November 2021 10:48 AM  |   Last Updated: 21st November 2021 10:48 AM   |  A+A-

A health official shows Covaxin dose.

A health official shows Covaxin dose. (File Photo| Shekhar Yadav, EPS)

Express News Service

NEW DELHI: A research led by the National Institute of Immunology, apart from several other government institutions, has for the first time confirmed Covaxin-induced immune memory, indicating that the COVID-19 vaccine is capable of ensuring long term protection against severe disease.

The study, funded by the Centre's department of biotechnology has shown that T and B cell memory responses generated by Covaxin measures similar to the memory responses generated by the natural infection.

The finding is significant, especially as various researches have now proven that antibodies - another marker of a vaccine's efficacy - generated after being vaccinated with Covaxin is significantly lower as compared to Covishield, the other vaccine used in India.

Covaxin is India's first fully indigenously developed COVID-19 vaccine, developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR. Recently, it was granted emergency use listing by the WHO.

The latest report led by NII scientists which determined the magnitude, quality and persistence of cellular and humoral memory responses up to six months after vaccination with Covaxin, says the quantity of vaccine-induced spike and nucleoprotein antibodies is comparable to that following natural infection and the antibodies are detectable up to six months.

The RBD-specific antibodies decline in the range of 3 to 10-fold against SARS-CoV-2 variants in the order of  alpha, delta, beta, with no observed impact of gamma and kappa variants. "We found that the vaccine induces memory B cells, similar to natural infection, which are impacted by virus variants in the same order as antibodies," noted the researchers.

The findings released in a pre-print for medical research establish that the inactivated vaccine Covaxin induces robust immune memory to SARS-CoV-2 and variants of concern, which persist for at least six months after vaccination.

"This study has implication for future vaccine development, guidance for use of inactivated virus vaccine, and booster immunisation," it said.

Immune memory up to six months

The findings establish that the inactivated vaccine Covaxin induces robust immune memory to SARS-CoV-2 and variants of concern, which persist for at least six months after vaccination



Comments(1)

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

  • Cherla Murthy

    happy to know that india designed vaccin is superior to its compititors
    6 months ago reply
flipboard facebook twitter whatsapp